We examined sequential serum samples from 12 patients with well-characterized posttransfusion non-A, non-B hepatitis who had an acute, resolving self-limited type of clinical course for the presence of antibody to the hepatitis C virus nucleocapsid (core) protein (p22) expressed by a recombinant bac
Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus
โ Scribed by Kendo Kiyosawa; Takeshi Sodeyama; Eiji Tanaka; Yukio Gibo; Kaname Yoshizawa; Yoshiyuki Nakano; Seiichi Furuta; Yoshihiro Akahane; Kusuya Nishioka; Robert H. Purcell; Harvey J. Alter
- Publisher
- John Wiley and Sons
- Year
- 1990
- Tongue
- English
- Weight
- 523 KB
- Volume
- 12
- Category
- Article
- ISSN
- 0270-9139
No coin nor oath required. For personal study only.
โฆ Synopsis
To clarify the relationship between hepatitis C virus infection and the development of hepatocellular carcinoma as sequelae of non-A, non-B posttransfusion hepatitis, 231 patients with chronic non-A, non-B hepatitis (96 with chronic hepatitis, 81 with cirrhosis and 64 with hepatocellular carcinoma) were analyzed for antibody to hepatitis C virus and were compared with 126 patients with chronic hepatitis B (60 with chronic hepatitis, 46 with cirrhosis and 29 with hepatocellular carcinoma). Antibody to hepatitis C virus was detected in 89.6%, 86.4% and 94.4% of patients with non-A, non-B hepatitkrelated chronic hepatitis, cirrhosis and hepatocellular carcinoma, respectively, compared with 6%, 17.4% and 34.6% with similar diseaaea related to hepatitis B. A history of transfusion was documented in 52%, 33% and 42% of anti-hepatitis C virugpositive cases of chronic hep atitis, cirrhosis and hepatocellular carcinoma. The mean intervals between the date of tranefaeion and the date of diagnosis of anti-hepatitis C virus-positive chronic hepatitis, cirrhosis and hepatoeellular car- cinoma were 10, 21.2 and 29 yr, respectively. In 21 patients with tradbsion-associated hepatocellular carcinoma, anti-hepatitis C virus wae pweent in each serial sample available for testing, including samples obtained up to 14 yr before the diagnosis of hepatocellular carcinoma. These data suggest the slow, sequential progreesion from acute hepatitis C virusrelated non-A, non-B hepatitis through chronic hep atitis and cirrhosis to hepatocellular carcinoma and support a c a d association between hepatitis C virus and hepatocellular carcinoma. (HEPATOLOGY 1990; 12: 671875.)
๐ SIMILAR VOLUMES
In a retrospective study, antibody to hepatitis C virus (anti-HCV antibody) was measured in 80 patients with acute viral hepatitis (type A, 18; type B, 21; type non-A,non-B, 41). Anti-HCV antibody was found in 12 of 20 patients (60%) with non-A,non-B post-transfusion hepatitis (NANB-PTH) and in 9 of
To assess the contribution of hepatitis C virus to non-A, non-B fulminant hepatitis in Japan, we compared 10 mqjor clinical features among 7 patients with type B fulminant hepatitis (type B group), 13 patients with non-A, non-B fulminant hepatitis with evidence of hepatitis C virus infection (type C
In an effort to determine the cause of non-A-E hepatitis, a retrospective study was undertaken on a group of patients with hepatitis but without serological infection markers of hepatitis viruses A-E. A total of 60 patients admitted to Beijing Ditan Hospital during the period of September 1997 and S
To study the role of hepatitis C virus in non-A, non-B chronic hepatitis, 49 liver biopsy samples from 40 patients with non-A, non-B chronic hepatitis and 9 control patients were analyzed by complementary DNA/polymerase chain reaction. Two segments of the HCV genome, one in the nonstructural region